TLTom Lapidus

Tom Lapidus

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tom Lapidus has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Alaa Jolani

    Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    1 shared publication
  • Amnon Peled

    Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    1 shared publication
  • Andrew M. George

    Division of Human Genetics Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

    1 shared publication
  • Cassandra Ligh

    Division of Plastic and Reconstructive Surgery Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

    1 shared publication
  • Elina Zorde-Khvalevsky

    Goldyne Savad Institute of Gene Therapy, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    1 shared publication
  • Gal Goldstein

    The Pediatric Hemato-Oncology Department, Hadassah- Hebrew University Medical Center, Jerusalem, Israel

    1 shared publication

Latest Publications

  • Open Access

    Irinotecan Modulates Immune Checkpoints in Neuroblastoma

    by Tom Lapidus, Elina Zorde-Khvalevsky, Alaa Jolani, Gal Goldstein, Amnon Peled

    Background: Neuroblastoma (NBL) is the most common extracranial solid tumor in children, with a 50% survival rate in high-risk cases. Chemotherapy combination with immunotherapy is central to HR-NBL treatment. Aim: This study aimed to explore how Irinotecan influences the immune landscape of NBL cells, particularly focusing on the modulation of immune checkpoints relevant to future chemo-immunotherapy strategies. Methods: Two neuroblastoma cell lines, SK-N-BE(2) and SH-SY5Y, were exposed to sub-lethal doses of Irinotecan and IFN-γ. Flow cytometry assessed the expression of immune markers, including GD2, CD47, MHC I, and PD-L1. We also examined phagocytosis by macrophages and T-cell-mediated killing. In vivo studies using a neuroblastoma mouse model assessed the effects of Irinotecan and PBMC injections. Soluble CD47 was also measured in cell culture supernatants and exploratory patient plasma samples. Results: Treatment exposure was associated with modulation of several immune-related markers, including GD2, CD47, PD-L1, and MHC class I. While Irinotecan reduced macrophage-mediated phagocytosis, this effect was reversed by the addition of anti-CD47 antibodies. T-cell-mediated killing was enhanced when NBL cells were pre-treated with Irinotecan. In vivo studies showed that the combination of PBMCs and Irinotecan resulted in reduced tumor burden compared to either treatment alone. Furthermore, CD47 expression was detectable in-patient plasma, suggesting that soluble CD47 may warrant exploration in larger future cohorts. Conclusion: This pilot study suggests that irinotecan may modulate key immune checkpoints in neuroblastoma. These results supports further investigation of rational chemo-immunotherapy combinations, including GD2 and CD47-targeted combination strategies.

  • Open Access

    Breast Findings in Females With Beckwith–Wiedemann Syndrome

    by Liron D. Grossmann, Andrew M. George, Tom Lapidus, Cassandra Ligh, Suzanne P. MacFarland, Jennifer M. Kalish

    Beckwith–Wiedemann syndrome (BWS) is an overgrowth condition caused by epigenetic defects on chromosome 11p15. Children with BWS have a predisposition to embryonal tumors such as Wilms tumor and hepatoblastoma. However, few reports of breast tumors in females with BWS have been published and the risk of malignancy and need for screening remains unknown. In this report, we describe six adolescent or adult females with BWS who developed benign or malignant breast tumors. Additionally, we conducted a review of the literature to compare our findings with previously reported cases.